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Recurrent CNVs and SNVs at the NPHP1 Locus
Contribute Pathogenic Alleles to Bardet-Biedl Syndrome
Anna Lindstrand,1,9 Erica E. Davis,1 Claudia M.B. Carvalho,2,3 Davut Pehlivan,2 Jason R. Willer,1
I-Chun Tsai,1 Subhadra Ramanathan,4 Craig Zuppan,5 Aniko Sabo,6 Donna Muzny,6 Richard Gibbs,6
Pengfei Liu,2 Richard A. Lewis,2 Eyal Banin,7 James R. Lupski,2,8 Robin Clark,4 and Nicholas Katsanis1,*
Homozygosity for a recurrent 290 kb deletion of NPHP1 is the most frequent cause of isolated nephronophthisis (NPHP) in humans. A
deletion of the same genomic interval has also been detected in individuals with Joubert syndrome (JBTS), and in the mouse, Nphp1
interacts genetically withAhi1, a known JBTS locus. Given these observations, we investigated the contribution ofNPHP1 in Bardet-Biedl
syndrome (BBS), a ciliopathy of intermediate severity. By using a combination of array-comparative genomic hybridization, TaqMan
copy number assays, and sequencing, we studied 200 families affected by BBS.We report a homozygousNPHP1 deletion CNV in a family
with classical BBS that is transmitted with autosomal-recessive inheritance. Further, we identified heterozygous NPHP1 deletions in two
more unrelated persons with BBS who bear primary mutations at another BBS locus. In parallel, we identified five families harboring an
SNV in NPHP1 resulting in a conserved missense change, c.14G>T (p.Arg5Leu), that is enriched in our Hispanic pedigrees; in each case,
affected individuals carried additional bona fide pathogenic alleles in another BBS gene. In vivo functional modeling in zebrafish
embryos demonstrated that c.14G>T is a loss-of-function variant, and suppression of nphp1 in concert with each of the primary BBS
loci found in our NPHP1-positive pedigrees exacerbated the severity of the phenotype. These results suggest that NPHP1 mutations
are probably rare primary causes of BBS that contribute to the mutational burden of the disorder.Nephrocystin-1 is a ciliary protein encoded by NPHP1 on
human chromosome 2q13 (MIM 607100; RefSeq accession
number NM_000272.3; GI, 189491772). The genetic struc-
ture surrounding the gene and locus includes flanking
330 kb inverted low-copy repeats (LCR) that have 45 kb
direct repeats embedded within them; this genomic archi-
tecture renders the locus susceptible to genomic instability
mainly via nonallelic homologous recombination
(NAHR).1 A common 290 kb recurrent microdeletion
with breakpoints located within the smaller direct repeats
is present in approximately 1/400 normal individuals of
northern European descent (estimated from the Database
of Genomic Variants [DGV]). Homozygous deletions
have never been detected in controls, suggesting that loss
of NPHP1 gives rise to penetrant pathology. However, the
clinical expressivity of the homozygous deletion can be
variable. In most cases reported, the deletion has
been causally associated with isolated nephronophthisis
(NPHP [MIM 256100])1,2 or NPHP and retinal degenera-
tion (Senior-Loken syndrome [SLS] [MIM 266900]);3 how-
ever, rare deletion cases have also been identified with
Joubert syndrome (JBTS [MIM 213300]), a severe ciliopathy
hallmarked by developmental delay and central nervous
system malformations.4 Multiple in vivo and in vitro
studies have demonstrated physical interaction, protein
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The Amand other ciliary proteins that include nephrocystin-3,
nephrocystin-4, and inversin.5–9 Moreover, a dosage-sensi-
tive interaction between Nphp1 and Ahi1, for which the
human ortholog is responsible for approximately 10% of
JBTS,10 has also been shown in rodent models; mice defi-
cient for both proteins have a more severe retinal pheno-
type than do the single-gene knockouts.11
These observations prompted us to ask whether NPHP1
harbors alleles that are contributory to other ciliopathies.
To this end, we queried NPHP1 mutations in a cohort
of individuals with Bardet-Biedl syndrome (BBS [MIM
209900]), a rare (1:13,500–1:160,000) multisystemic cili-
opathy characterized by retinal degeneration, obesity,
polydactyly, mental retardation, renal dysfunction, and
hypogonadism; BBS is also underscored by extensive
genetic heterogeneity, allelic overlap with other ciliopa-
thies, and both recessive and oligogenic forms of inheri-
tance.12–16
First, we tested the copy-number status of NPHP1 in 200
BBS-affected families (82.5% of individuals of European
ancestry, 15% of Arab ancestry, 2.5% of Hispanic origin)
and 229 control subjects of European descent. This anal-
ysis was part of a custom high-resolution oligonucleotide
array comparative genomic hybridization (aCGH) scan of
772 genes prioritized from the ciliary proteome;17 at the
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distributed across the intragenic coding and noncoding
regions with an average resolution of 100 bp and 500 bp,
respectively. The experiments were performed according
to the manufacturer’s recommendations with minor
modifications via whole-genome amplified DNA in BBS
cases and genomic DNA in controls.18 Additional individ-
uals from our pedigrees, as well as confirmatory analysis of
candidate CNVs, were genotyped by TaqMan copy-
number assays performed according to the manufacturer’s
recommendations. We used three different assays, located
in exon 1 (Hs00036264_cn), exon 10 (Hs00095856_cn),
and exon 20 (Hs00002984_cn) of NPHP1 (RefSeq
NM_000272.3; UCSC Genome Browser build hg19). Both
the usage of human DNA samples and model organisms
has been reviewed and approved by ethics board and
animal care and use committees at Duke University.
Informed consent was obtained before individuals were
included in the study.
We identified three BBS-affected families in which the
NPHP1 recurrent deletion segregated with disease: one
consanguineous Hispanic pedigree with a homozygous
deletion (RC2), one consanguineous Israeli family with a
heterozygous deletion (family 44), and one pedigree of
northern European descent (AR704) also bearing a hetero-
zygous deletion (Table 1, Figures 1 and 2). The deletion was
not detected in any of our control samples. Moreover, to
obtain a more accurate assessment of the frequency of
the NPHP1 deletion in the general population, and thus
the power of the analysis, we combined our experimental
control data with publicly available data from a genome-
wide copy-number variant (CNV) screen by Itsara et al.19
In this data set, heterozygous deletions were detected in
2/1,607 European controls.
Overall, we observed a deletion incidence of 1.5% of
BBS-affected pedigrees (3/200). Although a rare event,
data from the total BBS cohort versus the combined
control data sets (our 229 controls plus the Itsara et al.19
set) showed a significant enrichment of the NPHP1 dele-
tion allele in BBS (p ¼ 0.008, Fisher’s exact test). These
data were likewise significant when compared to the entire
DGV mixed population control data from 20,086 individ-
uals (p ¼ 0.011, chi-square with Yates correction). These
findings suggest that the NPHP1 deletion may contribute
to BBS.
Next, we turned our attention to point mutations.
We selected probands from 96 BBS-affected families
without preselection for known mutations or CNVs, we
PCR amplified all NPHP1 (RefSeq NM_000272.3, hg19)
coding exons and splice junctions, and we sequenced
them according to standard Sanger methodology (primers
and PCR conditions are available on request). We identi-
fied a single heterozygous variant that encoded a missense
change, c.14G>T (p.Arg5Leu; rs190983114; RefSeq
NM_000272.3; hg19), in three BBS-affected families (Table
1, Figure 2) of Hispanic (n ¼ 2; RC1, AR888) or northern
European (n ¼ 1; DM012) origin. The variant position is
evolutionarily invariant in all 39 species with a detectable746 The American Journal of Human Genetics 94, 745–754, May 1, 2NPHP1 ortholog and is present in ultrarare frequencies in
the Exome Variant Server database (EVS) (6/13,000 with
an equal MAF of 0.04% in either European American [EA]
or African American [AA] samples). To replicate this
finding, we assessed the prevalence of the c.14G>T change
in the second half of our BBS cohort by Sanger sequencing
of NPHP1 exon 1; we detected two additional BBS-affected
families (AR082 and R1) that were heterozygous for the
c.14G>T allele; both families were of Hispanic origin.
Combined, we found that 2.5% of our overall cohort
(5/200 families) carried the c.14G>T allele, which, similar
to the deletion burden in our cohort, represents an
apparent enrichment compared to controls.
We were struck by the fact that 4/5 of families with the
c.14G>T allele were of Hispanic origin, a subset that is
heavily underrepresented in our cohort, with only
14/200 families (n ¼ 4/14 Hispanics with NPHP1
c.14G>T; MAF 28%). This finding represents a significant
enrichment of this allele compared to EA and AA controls
(MAF < 0.04%). Given that EVS is bereft of Hispanic
control data, and conscious of the fact that we might be
observing a population-specific variant, we sequenced
277 control individuals of Hispanic origin; although the
MAF of this allele was elevated in this population, the
enrichment in our BBS cohort remained significant (28%
versus 4.9% MAF%; p ¼ 0.04; Fisher’s exact test).
Our findings are reminiscent of the genetic architecture
of other BBS and ciliopathy loci, in which low-frequency
variants can contribute both causal and contributory
alleles to the disease burden13,20–26 but for which the
genetic data alone suggest association but are insufficient
to provide robust arguments for causality. We therefore
turned to functional assays. We reasoned that (1) if
NPHP1 is relevant to BBS pathology, then suppression
of the zebrafish ortholog of this gene should mimic the
previously established phenotypes of bbs morphants at
midsomitic stages26,27 and also give rise to renal defects;
and (2) if the c.14G>T allele is relevant to the function
of the protein and the clinical phenotype of the affected
individuals, this allele should fail to complement suppres-
sion of nphp1 in vivo.
The Danio rerio genome has a single zebrafish NPHP1
ortholog (nphp1 [RefSeq NM_001077170]; 56% protein
sequence identity with human NPHP1). We obtained a
previously published nphp1 translation-blocking (tb)
morpholino (MO)6 as well as a splice-blocking (sb) MO tar-
geting the junction of nphp1 exon 2/intron 2–3 (50-ACA
GATACAAGTCCTCTACCTCTGC-30; Gene Tools). We in-
jected progressively increasing sb-MO or tb-MO concentra-
tions (3–9 ng, sb; 2–6 ng, tb) into wild-type (WT) zebrafish
embryos at the 1–4 cell stage and we scored embryo
clutches for shortened body axes, broader somites, and
broad and kinked notochords at the 8–10 somite stage
according to previously established objective criteria.26
For each MO independently, we observed a dose-depen-
dent increase in both the number of affected morphants
and also the severity of the defects (Figure S1 available014
Table 1. Detected Mutations and Clinical Findings in Affected Individuals with NPHP1 Mutations
Subject; Origin
NPHP1 Mutation
(RefSeq NM_000272.3)
BBS Locus (Primary Causal
Locus unless Indicated Otherwise)
Zebrafish
Dataa RP Polydactyly Obesity Hypogonadism Renal Anomalies
Developmental
Delay
RC2-03; Latino NPHP1: del; hom BBS2b (RefSeq NM_031885.3):
c.367A>G (p.Ile123Val); hom
hypomorph yes yes no yes nephronophthisis yes
AR704-03;
N. European
NPHP1: del; het BBS10c (RefSeq NM_024685.3):
c.145C>T (p.Arg49Trp); het
null yes yes yes NA no yes
AR704-04;
N. European
NPHP1: del; het BBS10c (RefSeq NM_024685.3):
c.145C>T (p.Arg49Trp); het
null yes yes yes NA no yes
44/3; Israel NPHP1: del; het BBS7 (RefSeq NM_176824.2):
c.87_88delCA (p.His29Glnfs*12); hom
NA yes yes yes yes born with one kidney;
chronic renal failure;
kidney transplantation
yes
44/4; Israel NPHP1: del; het BBS7 (RefSeq NM_176824.2):
c.87_88delCA (p.His29Glnfs*12); hom
NA yes yes yes NA no yes
AR888-03; Latino NPHP1: c.14G>T
(p.Arg5Leu); het
BBS1 (RefSeq NM_024649.4):
c.1645G>T (p.Glu549*); het
NA yes yes yes ND impaired renal function;
kidney cysts; enlarged
kidney
yes
BBS1d (RefSeq NM_024649.4):
del exon1_11; het
NA
RC1-03; Latino NPHP1: c.14G>T
(p.Arg5Leu); het
BBS10 (RefSeq NM_024685.3):
c.926T>C (p.Leu309Pro); het
ND yes yes yes yes no yes
BBS10 (RefSeq NM_024685.3):
c.9_14delTTCTAT
(p.Ser3_Met5delinsArg); het
ND
DM012-003;
N. European
NPHP1: c.14G>T
(p.Arg5Leu); het
BBS10 (RefSeq NM_024685.3):
c.271dupT (Cys91Leufs*5); hom
NA yes yes yes no no yes
R1-04; Latino NPHP1: c.14G>T
(p.Arg5Leu); het
BBS9 (RefSeq NM_198428.2):
c.1536A>G [p.(¼)]; hom
ND yes ND ND ND ND ND
R1-05; Latino NPHP1: c.14G>T
(p.Arg5Leu); het
BBS9 (RefSeq NM_198428.2):
c.1536A>G [p.(¼)]; hom
yes ND ND ND ND ND
AR082-03; Latino NPHP1: c.14G>T
(p.Arg5Leu); het
BBS9 (RefSeq NM_198428.2):
c.1789C>T (p.Gln597*); hom
NA yes ND ND ND ND ND
Abbreviations are as follows: RP, retinitis pigmentosa; del, deletion; het, heterozygous; hom, homozygous; NA, not applicable (affected individual is female); ND, not determined.
aData from Zaghloul et al.26
bPutative second-site modulator
cHeterozygous change, unclear whether causal locus
dPublicly available in dbVar (study ID: nstd93)
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Figure 1. NPHP1 Deletions in Individuals
with BBS
(A) Schematic of human chromosome 2. A
vertical red line indicates the position of
NPHP1 (RefSeq NM_000272.3) at 2q13.
(B) A zoomed depiction of theNPHP1 locus
with a schematic illustration of exons
(vertical black bars). The genomic location
on chromosome 2 (in Mb) is shown.
c.14G>T (p.Arg5Leu) is indicated with a
black star.
(C) High-resolution results from the aCGH
analyses in individuals RC2-03 (top),
AR704-03 (middle), and 44/3 (bottom)
are visualized as a plot. The horizontal
blue bar represents NPHP1. Individual
dots represent specific oligonucleotide
probes and are indicated as black (normal
copy number), red (copy number gain),
and green (copy number loss) compared
to a reference sample. The normalized
log2 ratios of the Cy5/Cy3 intensity values
for cases versus controls are shown on the
y axis.
(D) Segregation of the NPHP1 deletion by
Taqman copy number analysis using a
probe (Hs00002984_cn) located within
the NPHP1 locus; individuals 44/2, 44/3,
44/4, AR704-02, AR704-03, AR704-04,
RC2-01, and RC2-02 harbor a heterozy-
gous deletion and RC2-03 has a homozy-
gous deletion. Error bars were calculated
by the CopyCaller Software and represent
the copy number range of triplicate
reactions.online) that phenocopied the phenotypes observed in
numerous ciliopathy morphants, including all tested BBS
genes.20,22,23,27–30 To test sb-MO efficiency, we harvested
whole embryos in Trizol (Invitrogen) for total RNA extrac-
tion and reverse transcribed oligo-dT primed cDNA (Super-
script III, Invitrogen) for PCR. An aberrant splicing product
was detected in sb-MO-injected embryos (Figure S1).
To test forMO specificity, we coinjectedMOwith capped
human WT NPHP1 mRNA. In brief, to generate human
NPHP1 message, we cloned the full-length NPHP1 open
reading frame into the pCS2þ plasmid, linearized with
NotI, and performed in vitro transcription with the
SP6 mMessage mMachine kit (Ambion). Coinjection of
200 pg of WT human NPHP1 mRNA with MO (3 ng sb-
MO; 2 ng tb-MO) resulted in a significant rescue of mor-
phant phenotypes (55% versus 39% abnormal for sb-MO
versus sb-MOþWT; p ¼ 0.003; Figure 3; n ¼ 60–62 em-748 The American Journal of Human Genetics 94, 745–754, May 1, 2014bryos/injection and 69% versus 45%
abnormal for tb-MO versus tb-
MOþWT; p < 0.0001; Figure S1; n ¼
31–41 embryos/injection). We then
used the gastrulation phenotype to
test the pathogenicity of the hetero-
zygous c.14G>T NPHP1 variant by
comparing the ability of equivalent
doses of NPHP1 WT or c.14G>U
mRNA to rescue the nphp1 sb-MO-induced defects. Coinjection of nphp1 sb-MO with human
NPHP1 mRNA harboring the c.14G>U mutation was
significantly worse from embryo clutches injected with
sb-MO coinjected with WT mRNA, suggesting that the
mutation impedes NPHP1 function (Figures 3A and 3B).
Injection of mutant NPHP1 mRNA was indistinguishable
from wild-type injection (p ¼ 0.79), but injection of
decreasing doses of c.14G>U mRNA alone resulted in a
dose-dependent decrease of affected embryos (Figure S2),
which indicates indirectly the decreased function
conferred by the c.14G>T mutation.
In parallel, we tested two missense variants mined from
EVS that had both a modest allele frequency (>1% MAF)
and an apparent ethnicity-specific enrichment similar to
c.14G>T (c.115C>A, rs33958626, MAF 0.6% in AA versus
4% in EA; and c.689C>T, rs113450177, MAF 3.3% AA
versus 0% EA; RefSeq NM_000272.3; hg19). The efficiency
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Figure 2. Pedigrees of the Families with
NPHP1 Mutations
Pedigrees and BBS gene mutational anal-
ysis results in all families with NPHP1
mutations. Squares denote males and
circles denote females. Blackened symbols
represent the affected children and indi-
vidual identification numbers are given
below the symbols. Double lines indicate
consanguinity.of both variants to improve the nphp1 MO gastrulation
defects was not significantly different than that of WT
mRNA, lending further evidence in favor of the specificity
of the c.14G>T pathogenicity (Figure 3B, Table S1).
Next, we corroborated these findings in 4 day postfertili-
zation (dpf) zebrafish larva by using a phenotypic readout
directly relevant to NPHP. In brief, we reinjected sb-MO
and/or mRNA at identical doses to those used for the
gastrulation scoring and fixed embryos for whole-mount
immunostaining with anti-NaK ATPase antibody (a6F,
Developmental Studies Hybridoma Bank) as described.31
Although we did not observe significant cyst formation
in nphp1morphant batches (<1%), we did observe atrophy
and diminished convolution of the proximal tubule,
which is an orthologous renal feature consistent with
NPHP in humans32 (Figure 3C). Coinjection of sb-MO
with WT mRNA improved significantly this defect (61%
versus 30% affected for sb-MO versus WTþsb-MO, p <
0.0001, n ¼ 46 embryos/injection with masked scoring),
whereas embryo clutches injected with MO and
c.14G>U mRNA were significantly worse than WT rescue
(51% affected, p < 0.0001). These data corroborated our
CE studies and suggested further that c.14G>T is patho-
genic. Moreover, negative control variants c.115C>A andThe American Journal of Humac.689C>T both scored benign in this
assay, once again similar to the CE
studies (Figures 3C and 3D; Table S1).
In aggregate, our data indicate that
eight BBS-affected families bear loss-
of-function mutations in NPHP1
from either deletion CNVs or from a
deleterious point mutation (SNV).
We therefore asked (1) whether any
of these alleles might be genetically
necessary to drive the phenotype
under a recessive paradigm and
thus represent a Penetrant Mendeliz-
ing Variant (PMV); and (2) similar
to other ciliopathy loci, whether
the phenotype could be explained
by the amalgam of mutations at mul-
tiple loci.
We first segregated all pathogenic
variants in our families. In the family
with the homozygous NPHP1
deletion, segregation showed auto-somal-recessive inheritance, with each of the parents being
heterozygous carriers, as confirmed by a Taqman copy
number assay (Figures 1D and 2A). By contrast, in the other
two families with a heterozygous NPHP1 deletion, there
was no evidence of a second CNV in NPHP1, and
sequencing of all exons was likewise negative for candidate
pathogenic changes. These data suggested that this lesion
might be coincidental in these families or be contributory
to the genetic load of these pedigrees similar to what has
been observed for other BBS loci.13,14,20–26 We made
similar observations for the five families bearing the
c.14G>T allele, none of which carried additional NPHP1
pathogenic alleles that were detectable within the con-
straints of our methodology.
Given these observations, and the fact that the BBS
phenotype is more severe than what would be expected
typically from a homozygous NPHP1 deletion, we asked
whether our NPHP1-positive pedigrees might bear addi-
tional pathogenic lesions in the known BBS loci; therefore,
we performed Sanger-based sequencing analysis of the
BBS1-16 exons and splice junctions, which together
account for ~75% of the disease burden in BBS.15,33
Consistent with the NPHP1 deletion being the primary
driver of BBS, sequencing of DNA from individuals inn Genetics 94, 745–754, May 1, 2014 749
Figure 3. Morpholino-Induced Suppression of nphp1 in Zebrafish Embryos Generates Gastrulation Defects and Abnormal Renal
Morphology
(A) Live dorsal and lateral views of normal embryos and class I and class II morphants are shown. Live images of embryos were acquired
on a Nikon AZ100 microscope at 83 magnification, with image capture facilitated by NIS Elements software (Nikon).
(B) Quantification of live scoring of nphp1MOand humanmRNA (co)injections. Embryos were injected with the indicated dose (2 ng sb-
MO and/or 200 pgNPHP1mRNA) and scored live according to criteria shown. n¼ 48–65 embryos/injection, repeated at least twice; with
masked scoring; all comparisons were made using c2 tests; *p < 0.002; NS, not significant; see Table S1 for p values. c.115C>A
(rs33958626) and c.689C>T (rs113450177) have similar minor allele frequencies (MAF; 4% in European Americans and 3.3% in African
Americans) to that of c.14G>T (rs190983114) in our overall BBS cohort (2.5%), but result in rescue not significantly different from
WT mRNA.
(C) Lateral views of representative larva fluorescently stained at 4 days postfertilization (dpf) with anti-NaK ATPase antibody (a6F, Devel-
opmental Studies Hybridoma Bank) to demarcate renal tubules. In comparison to controls, embryos injected with nphp1 sb-MO have
atrophy and reduced convolution of the proximal tubule. Inset area indicated by dashed green line.
(D) Quantification of renal phenotyping of nphp1MO and humanmRNA (co)injections. Embryos were injected with the indicated dose
(2 ng sb-MO and/or 200 pg NPHP1 mRNA) and immunostained with anti-NaK ATPase antibody and scored as normal or affected
(as shown in panel C), n ¼ 46–51 embryos/injection, repeated at least twice; with masked scoring; all comparisons were made with
c2 tests; *p < 0.05; NS, not significant; see Table S1 for p values.family RC2 yielded no biallelic mutations under a recessive
model. These data, together with the fact that the NPHP1
deletion has never been observed in homozygosity in
control individuals, indicates that this lesion is the most
likely primary driver of the disease in the family, or PMV,
potentially defining a new BBS locus. Consistent with
this notion, phenotypic analysis of the affected individual
(RC2-03) that included a renal biopsy indicated that the
proband, in addition to his classical BBS features (retinal750 The American Journal of Human Genetics 94, 745–754, May 1, 2degeneration, polydactyly, developmental delay, hypogo-
nadism), was notable for tubular interstitial and glomer-
ular injury, findings uncommon in BBS34 but typical of
nephronophthisis (Figure 4).
Of note, individual RC2-03 harbors a homozygous BBS2
variant, c.367A>G (p.Ile123Val). This allele cannot be
causal to BBS, because it is present in homozygosity in
~4% of EA and 8% of Hispanic control subjects (rs11373;
dbSNP; RefSeq NM_031885.3; hg19). However, this014
Figure 4. Renal Biopsy on Individual RC2-03
Renal biopsy on RC2-03, showing moderate tubular atrophy and
interstitial fibrosis, with one obsolescent glomerulus (arrow). In
the context of this individual, the findings are consistent with
juvenile nephronophthisis. (Trichrome stain, original magnifica-
tion 3100.)change has been shown previously to be a functional
hypomorph that is enriched significantly and overtrans-
mitted in individuals with BBS,26 raising the possibility
that NPHP1 and BBS2 might interact genetically.
We similarly analyzed the coding regions of BBS1-1616
by Sanger sequencing in the other seven families. In
five of them, we identified a primary BBS driver locus.
In the other two families (AR888 and AR704), we evaluated
BBS1 and BBS10, respectively, for CNVs that could unmask
the second recessive allele. We identified a paternally
inherited 17.7 kb deletion of BBS1 (RefSeq NM_024649.4;
hg19) exons 1–11 (in AR888 in trans with a truncating
point mutation), thereby adding a sixth pedigree with
a characterized primary driver locus (Table 1, Figures 2
and S3). The causal locus in AR704 remains unclear; we
cannot rule out the possibility that AR704 harbors a
second BBS10 allele in a regulatory region, or that BBS10
functions as a second-site modulator to a hitherto uniden-
tified BBS gene.
Together, our CNV and sequencing data showed one
pedigree in which homozygous loss ofNPHP1 is coincident
with a homozygous hypomorph in BBS2; in the remaining
families, heterozygous NPHP1 loss-of-function alleles are
coinherited with mutations in each of BBS1, BBS7, BBS9,
and BBS10. We note that these predominant causal loci
in the NPHP1-mutation-bearing pedigrees differ somewhat
from the reported relative contributions of BBS genes
to the disorder,15,33 which may either be a chance event
or may be suggestive of a unique biochemical relationship
between NPHP1 and these BBS proteins.
As a first step toward investigating these possibilities,
we asked whether genetic interaction between NPHP1
and the primary BBS driver loci can exacerbate the severity
of disease in a manner reminiscent of the reported NPHP1-The AmAHI1 interaction,11 as well as the interaction reported
previously for various binary combinations of ciliop-
athy13,20,22–26,35–38 and nonciliopathy21 loci. We therefore
coinjected subeffective doses of the nphp1 sb-MO (0.5 ng)
with each of bbs1 (3 ng), bbs2 (1 ng), bbs7 (3.5 ng), bbs9
(2 ng), and bbs10 (4 ng)26 (Figure 5, Table S1). In each pair-
wise combination, gastrulation phenotypes were signifi-
cantly more severe in the double MO injected embryos
compared to the single MO injections alone (n ¼ 61–255
embryos/injection; masked scoring). Similarly, the pres-
ence of proximal renal tubule atrophy in 4 dpf larva
showed that for each pairwise combination, renal pheno-
types were exacerbated significantly in comparison to
single MO injections alone (n ¼ 16–95 embryos/injection;
masked scoring). Together, these data indicate that sup-
pression of NPHP1 activity, in combination with loss of
function of any tested BBS locus, can interact to exacerbate
phenotypic severity. We do not have the resolution to
determine whether these effects are additive or multiplica-
tive, although our functional studies are more consistent
with an additive model.
Given that we discovered a single BBS-affected family
with recessive NPHP1 deletions, it will be necessary to
identify additional individuals who fulfill BBS clinical
criteria but have causal molecular lesions at the NPHP1
locus. Browsing the Database of Chromosome Imbalance
and Phenotype in Humans using Ensembl Resources
(DECIPHER) identified one additional case with the
homozygous NPHP1 deletion. The phenotypic informa-
tion available (oculomotor apraxia; delayed speech and
language development; intellectual disability) partially
overlaps with BBS (but also with JBTS) but only for neuro-
cognitive features that are typical triggers for ordering
clinical aCGH testing. However, our data potentially
extend the phenotypic spectrum of NPHP1 loss of func-
tion, wherein homozygous deletion of the locus can give
rise to ciliopathy phenotypes in the intermediate contin-
uum between classical isolated NPHP and the severe
JBTS phenotype. These data predict that individuals
affected by other ciliopathies might also bear similar
lesions and suggest that extending the diagnostic analysis
of ciliary disease cases to include this NPHP1 CNV, and
potential CNVs at other ciliopathy loci,17 might inform
further the genetics of ciliopathies and other complex
traits.
More broadly, our data also suggest that NPHP1 mirrors
other ciliopathy loci, contributing both causal and/or
contributory alleles to the genetic burden of the disease.
The observed deletion removes NPHP1 and a fragment of
the neighboring gene MALL; however, previous studies
have detected the heterozygous deletion in trans with a
coding change in NPHP1 in persons with NPHP, but they
did not detect mutations in MALL.2 As such, although we
cannot formally exclude the contribution of MALL to
BBS, we consider that unlikely.
Our observations, together with previous studies, sug-
gest that the NPHP1 lesion might not be deterministic forerican Journal of Human Genetics 94, 745–754, May 1, 2014 751
Figure 5. nphp1 Interacts Genetically
with All Primary BBS Loci Identified in
BBS Cases with NPHP1 Mutations
(A) Gastrulation defects in midsomitic em-
bryos. Coinjection of a subeffective dose of
nphp1 sb-MO together with each of bbs1,
bbs2, bbs7, bbs9, and bbs10 MOs signifi-
cantly increase the gastrulation phenotype
compared to the same dose injected alone.
n ¼ 61–255 embryos/injection, 0.5 ng of
nphp1 sb-MO, 3 ng of bbs1-MO, 1 ng
of bbs2-MO, 3.5 ng of bbs7-MO, 2 ng of
bbs9-MO, and 4 ng of bbs10-MO was
used, scoring as in Figure 3A.
(B) Proximal tubule defects in 4 dpf
larva. Coinjection of a subeffective dose
of nphp1 sb-MO together with each of
the five bbs MOs (same doses as in A) in-
crease significantly the renal phenotype
at 4 dpf compared to the same dose in-
jected alone. n ¼ 16–95 embryos/injec-
tion, scoring as in Figure 3B. See Table S1
for p values.renal disease. First, mouse breeding experiments have
shown that the Nphp1-Ahi1 interaction can exacerbate
retinal pathology.11 Second, although the individual
(RC2-03) with the homozygous NPHP1 deletion does
manifest hallmarks of NPHP-like renal pathology, only
two of our other ten BBS-affected individuals with hetero-
zygousNPHP1 lesions had renal defects. This is not surpris-
ing, given that we interrogated only a small fraction of the
ciliary proteome (or the genome) and that, as emerging
data suggest, the primary cilium is sensitive to trans-
epistasis that can either exacerbate or ameliorate the
phenotype, as exemplified by the protective effect of
loss-of-function Bbs6 mutations on Cep290 and the
likewise protective effect of loss-of-function axonemal
mutations on a genetic background sensitized by PKD
mutations in mice.36,38
In the present work, the challenges of interpreting the
contribution of heterozygous rare alleles in the context752 The American Journal of Human Genetics 94, 745–754, May 1, 2014of primary causal lesions are exacer-
bated by the identification of alleles
with ethnic-specific enrichment. The
c.14G>Tallele is ultrarare in northern
European and African American con-
trol subjects (MAF < 0.04%) but is
elevated in Hispanics, a population
that has been undersampled for BBS.
In these instances, statistical argu-
ments alone remain constrained by
the availability of cases and appro-
priate controls. Thus, the synthesis
of population data with rigorous
functional studies of allele effect
may aid interpretation of the poten-
tial functional consequences of the
burden of rare alleles and their impacton the penetrance and expression of the disease in an
ethnicity-specific manner.39Supplemental Data
Supplemental Data include three figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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